CompletedNCT00810667
Add-on treatment and thinking skills in schizophrenia
About this title
Read the official source — NCT00810667Researchers compared Lu AE58054 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Lu AE58054 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Liège and 24 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNovember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 124
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France, Belgium, Germany, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00810667
- Official title
Show the full official title
A Randomised, Double-blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Liège, Belgium · Bordeaux, France · Brumath, France
21 more locations
- Nîmes, France
- Toulouse, France
- Dresden, Germany
- Hong Kong, Hong Kong
- Brescia, Italy
- Naples, Italy
- Bełchatów, Poland
- Bialystok, Poland
- Leszno, Poland
- Lodz, Poland
- Lublin, Poland
- Piekary Śląskie, Poland
- Skorzewo, Poland
- Torun, Poland
- Warsaw, Poland
- Września, Poland
- Hualien City, Taiwan
- Keelung, Taiwan
- Tainan, Taiwan
- Chiang Mai, Thailand
- China
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Lu AE58054 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Lu AE58054 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
